PEL
MCID: LYM126
MIFTS: 44

Lymphoma Aids Related (PEL)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphoma Aids Related

MalaCards integrated aliases for Lymphoma Aids Related:

Name: Lymphoma Aids Related 52
Primary Effusion Lymphoma 52 58 17
Lymphoma, Aids-Related 17 71
Pel 52 58
Body Cavity-Based Lymphoma 58
Aids Related Lymphoma 52
Aids-Related Lymphoma 52
Lymphoma Aids-Related 54

Characteristics:

Orphanet epidemiological data:

58
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D054685
ICD10 via Orphanet 33 C83.8
UMLS via Orphanet 72 C1292753
Orphanet 58 ORPHA48686
UMLS 71 C0085090

Summaries for Lymphoma Aids Related

MalaCards based summary : Lymphoma Aids Related, also known as primary effusion lymphoma, is related to central nervous system lymphoma and lymphoma. An important gene associated with Lymphoma Aids Related is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and JAK-STAT signaling pathway (KEGG). The drugs Ketamine and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and endothelial, and related phenotypes are dyspnea and abdominal pain

Wikipedia : 74 AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome... more...

Related Diseases for Lymphoma Aids Related

Diseases related to Lymphoma Aids Related via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 central nervous system lymphoma 29.8 MYC BCL6
2 lymphoma 29.6 TCL1A MYC BCL6
3 castleman disease 29.5 IL7 BCL6
4 reticulosarcoma 29.3 MYC BCL6
5 plasmablastic lymphoma 29.2 MYC BCL6
6 diffuse large b-cell lymphoma 29.2 TCL1A MYC BCL6
7 mature b-cell neoplasm 29.2 MYC BCL6
8 lymphoblastic lymphoma 29.1 MYC BCL6
9 peripheral t-cell lymphoma 29.1 TCL1A BCL6
10 myeloma, multiple 29.0 MYC IL7 BCL6
11 b-cell lymphoma 28.8 TCL1A MYC BCL6
12 follicular lymphoma 28.7 MYC BCL6
13 acquired immunodeficiency syndrome 28.7 MYC BCL6
14 leukemia, acute myeloid 28.4 MYC IL7 BCL6
15 lymphoma, non-hodgkin, familial 28.2 TCL1A MYC IL7 BCL6
16 burkitt lymphoma 28.0 TCL1A MYC IL7 BCL6
17 leukemia, chronic lymphocytic 28.0 TCL1A MYC IL7 BCL6
18 hemopericardium 10.5
19 pericardial effusion 10.5
20 encephalopathy, progressive, with or without lipodystrophy 10.4
21 cardiac tamponade 10.3
22 liver cirrhosis 10.3
23 lymphoproliferative syndrome 10.3
24 hepatitis c virus 10.2
25 primary central nervous system lymphoma 10.2
26 pancytopenia 10.1
27 pemphigus 10.1
28 lymphoma, hodgkin, classic 10.0
29 immune deficiency disease 10.0
30 neutropenia 10.0
31 splenomegaly 10.0
32 rare tumor 10.0
33 human immunodeficiency virus type 1 10.0
34 amyloidosis, hereditary, transthyretin-related 10.0
35 autoimmune disease 10.0
36 osteogenic sarcoma 10.0
37 endocarditis 10.0
38 vaccinia 10.0
39 mast cell neoplasm 10.0
40 extracutaneous mastocytoma 10.0
41 amyloid neuropathy 10.0
42 antisynthetase syndrome 10.0
43 acute motor axonal neuropathy 10.0
44 nasopharyngeal carcinoma 10.0
45 adult t-cell leukemia 10.0
46 pleural tuberculosis 10.0
47 respiratory failure 10.0
48 leukemia 10.0
49 lymphopenia 10.0
50 47,xyy 10.0

Graphical network of the top 20 diseases related to Lymphoma Aids Related:



Diseases related to Lymphoma Aids Related

Symptoms & Phenotypes for Lymphoma Aids Related

Human phenotypes related to Lymphoma Aids Related:

58 31 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002094
2 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
4 abnormality of the peritoneum 58 31 hallmark (90%) Very frequent (99-80%) HP:0002585
5 pleural effusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0002202
6 pericardial effusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0001698
7 b-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012191
8 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721

Drugs & Therapeutics for Lymphoma Aids Related

Drugs for Lymphoma Aids Related (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
7
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
8
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
9
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
10
Morphine Approved, Investigational Phase 3 57-27-2 5288826
11
Mercaptopurine Approved Phase 3 50-44-2 667490
12
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
13
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
14
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
15
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
18
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
19 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
20 Renal Agents Phase 3
21 Cytochrome P-450 Enzyme Inhibitors Phase 3
22 Anti-Infective Agents, Urinary Phase 3
23 Anesthetics, Dissociative Phase 3
24 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
25 Antimetabolites Phase 3
26 Antiparasitic Agents Phase 3
27 Calcium, Dietary Phase 3
28 Antiprotozoal Agents Phase 3
29 Antifungal Agents Phase 3
30 Antibodies, Monoclonal Phase 3
31 Immunoglobulins Phase 3
32 Antibodies Phase 3
33 Analgesics Phase 3
34 Central Nervous System Depressants Phase 3
35 Narcotics Phase 3
36 Analgesics, Opioid Phase 3
37 Respiratory System Agents Phase 3
38 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
39 Antitussive Agents Phase 3
40 Anesthetics Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics, Intravenous Phase 3
43 Excitatory Amino Acid Antagonists Phase 3
44 Excitatory Amino Acids Phase 3
45 Liver Extracts Phase 3
46 Cola Phase 3
47 Liposomal amphotericin B Phase 3
48 Adjuvants, Anesthesia Phase 3
49
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
50
Valproic acid Approved, Investigational Phase 2 99-66-1 3121

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
4 A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
5 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
6 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
7 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
8 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
9 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
10 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support Unknown status NCT00003942 Phase 1, Phase 2
13 Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
14 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
15 Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
16 Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: "Stanford V Regimen" For "Low Risk" Patients, "EBVP Regimen" For "High Risk" Patients Unknown status NCT00003262 Phase 2 Stanford V regimen;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
17 Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
18 A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma Completed NCT00003388 Phase 2 cyclophosphamide;cytarabine;methotrexate;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
19 EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
20 Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
21 Pilot Study in AIDS-Related Lymphomas Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
22 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
23 Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma Completed NCT00799136 Phase 2 R-EPOCH and cART
24 Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002578 Phase 2 cytarabine;gallium nitrate;leucovorin calcium;methotrexate
25 A Phase II Trial of 72-Hour Continuous Infusion Bleomycin as Salvage Therapy in AIDS-Related and Immunocompetent Non-Hodgkin's Lymphoma Completed NCT00003110 Phase 2
26 Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa Completed NCT00049439 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
27 Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome Completed NCT00002348 Phase 2 Mitoguazone
28 A Randomized Pre-Phase II Trial of Interleukin-2, Interleukin-12, or No Additional Therapy Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003575 Phase 2 etoposide;ifosfamide
29 Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS Completed NCT00002940 Phase 2 hydroxyurea
30 A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
31 First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at "High Risk", Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Completed NCT01045889 Phase 2
32 A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma Completed NCT00389818 Phase 2 cyclophosphamide;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
33 AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy Completed NCT00267865 Phase 2 Methotrexate;Rituximab;Leucovorin
34 A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study Completed NCT00002621 Phase 2
35 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
36 High Dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation for HIV Lymphomas: A Phase IIA Study of Comparative Marking Using a Ribozyme Gene and a Neutral Gene Completed NCT00002221 Phase 2 Peripheral blood stem cells
37 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
38 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
39 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
40 An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases Completed NCT00002663 Phase 1, Phase 2
41 A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma Completed NCT00392990 Phase 2 Regimen A;Regimen B
42 Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma Completed NCT00392834 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;liposomal cytarabine;methotrexate;therapeutic hydrocortisone;vincristine sulfate
43 Oral Combination Chemotherapy in the Treatment of AIDS-Associated Hodgkin's Disease Completed NCT00003114 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
44 High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803) Completed NCT01141712 Phase 2 BCNU;Etoposide;Cytarabine;Melphalan
45 Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
46 Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide
47 Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas Recruiting NCT00006436 Phase 2 EPOCH
48 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa Active, not recruiting NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;cyclophosphamide;procarbazine hydrochloride
49 Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin’s Lymphomas. ANRS 085 Rituximab Terminated NCT00126243 Phase 2 rituximab;CHOP
50 Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD) Withdrawn NCT00024128 Phase 2 cyclophosphamide;cyclosporine

Search NIH Clinical Center for Lymphoma Aids Related

Genetic Tests for Lymphoma Aids Related

Anatomical Context for Lymphoma Aids Related

MalaCards organs/tissues related to Lymphoma Aids Related:

40
B Cells, T Cells, Endothelial, Liver, Bone, Kidney, Brain

Publications for Lymphoma Aids Related

Articles related to Lymphoma Aids Related:

(show top 50) (show all 1229)
# Title Authors PMID Year
1
Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. 61
31725418 2020
2
Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation. 61
31361614 2020
3
Kaposi's Sarcoma-Associated Herpesvirus-Encoded circRNAs Are Expressed in Infected Tumor Tissues and Are Incorporated into Virions. 61
31911496 2020
4
Specific Inhibition of Viral MicroRNAs by Carbon Dots-Mediated Delivery of Locked Nucleic Acids for Therapy of Virus-Induced Cancer. 61
31895530 2020
5
Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. 61
31705618 2020
6
T Cell Primary Effusion Lymphoma in an HIV-Negative Man with Liver Cirrhosis. 61
31956261 2020
7
USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue. 61
31666375 2020
8
KSHV/HHV8-positive large B-cell lymphomas and associated diseases: a heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap. 61
31527708 2020
9
Reconsideration of the first recognition of breast implant-associated anaplastic large cell lymphoma: A critical review of the literature. 61
32028122 2020
10
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
11
The Zebrafish Xenograft Platform-A Novel Tool for Modeling KSHV-Associated Diseases. 61
31861850 2019
12
Identification of viral SIM-SUMO2-interaction inhibitors for treating primary effusion lymphoma. 61
31830143 2019
13
Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells. 61
31857147 2019
14
Kaposi's Sarcoma-associated Herpesvirus Viral Interleukin 6 Signaling Upregulates Integrin Beta 3 Levels and is Dependent on STAT3. 61
31801855 2019
15
Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation. 61
31790497 2019
16
Targeting the Kaposi Sarcoma Herpesvirus ORF 21 tyrosine kinase and viral lytic reactivation by tyrosine kinase inhibitors approved for clinical use. 61
31826996 2019
17
Induction of Kaposi Sarcoma Associated Herpesvirus-encoded Thymidine Kinase (ORF21) by X-Box Binding Protein-1. 61
31801863 2019
18
Extracavitary primary effusion lymphoma in a post-transplantation patient. 61
31515799 2019
19
Primary effusion lymphoma in human immune deficiency (HIV)-negative non-organ transplant immunocompetent patients. 61
31846233 2019
20
CRISPR/Cas9-Mediated Knockout and In Situ Inversion of the ORF57 Gene from All Copies of the Kaposi's Sarcoma-Associated Herpesvirus Genome in BCBL-1 Cells. 61
31413125 2019
21
Primary Mediastinal Nodal and Extranodal Non-Hodgkin Lymphomas: Current Concepts, Historical Evolution, and Useful Diagnostic Approach: Part 1. 61
31567132 2019
22
Primary Mediastinal Nodal and Extranodal Non-Hodgkin Lymphomas: Current Concepts, Historical Evolution, and Useful Diagnostic Approach: Part 2. 61
31567129 2019
23
Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation. 61
31394407 2019
24
Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. 61
30764603 2019
25
Panniculitis-Like Presentation of Extracavitary Primary Effusion Lymphoma. 61
31592862 2019
26
The utility of multiparametric flow cytometry in the detection of primary effusion lymphoma (PEL). 61
29669178 2019
27
High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. 61
31253594 2019
28
Association of polymorphisms in NFκB1 promoter and NFκBIA gene with the development of antibodies against HHV-8 in HIV-infected individuals. 61
31344550 2019
29
Human herpesvirus 6, 7, and 8 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. 61
30844089 2019
30
Primary effusion lymphoma in a human immunodeficiency virus-negative patient with unexpected unusual complications: a case report. 61
31543075 2019
31
A herpesvirus transactivator and cellular POU proteins extensively regulate DNA binding of the host Notch signaling protein RBP-Jκ to the virus genome. 61
31308175 2019
32
Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. 61
31346082 2019
33
Novel Virus Related to Kaposi's Sarcoma-Associated Herpesvirus from Colobus Monkey. 61
31310220 2019
34
The current state of human immunodeficiency virus-associated lymphoma in Japan: a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry. 61
31111394 2019
35
EphA7 Functions as Receptor on BJAB Cells for Cell-to-Cell Transmission of the Kaposi's Sarcoma-Associated Herpesvirus and for Cell-Free Infection by the Related Rhesus Monkey Rhadinovirus. 61
31118261 2019
36
Human Herpes-8 virus copy to cell ratio: A diagnostic tool in primary effusion lymphoma. 61
30991238 2019
37
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. 61
31351487 2019
38
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. 61
31300418 2019
39
miRNAs and their roles in KSHV pathogenesis. 61
30951791 2019
40
The landscape of transcription initiation across latent and lytic KSHV genomes. 61
31188901 2019
41
Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. 61
30962205 2019
42
Kaposi's sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression. 61
31059555 2019
43
Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1. 61
30770900 2019
44
Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. 61
30671911 2019
45
Indolent primary effusion lymphoma-like lymphoma in the pericardium: A case report and review of the literature. 61
31073346 2019
46
Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient. 61
30328487 2019
47
Viral, immunologic, and clinical features of primary effusion lymphoma. 61
30782610 2019
48
Towards Better Understanding of KSHV Life Cycle: from Transcription and Posttranscriptional Regulations to Pathogenesis. 61
31025296 2019
49
Insulin-Like Growth Factor 2 Receptor Expression Is Promoted by Human Herpesvirus 8-Encoded Interleukin-6 and Contributes to Viral Latency and Productive Replication. 61
30541844 2019
50
Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. 61
30837213 2019

Variations for Lymphoma Aids Related

Copy number variations for Lymphoma Aids Related from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Lymphoma Aids Related

Search GEO for disease gene expression data for Lymphoma Aids Related.

Pathways for Lymphoma Aids Related

Pathways related to Lymphoma Aids Related according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.97 TCL1A MYC IL7
2
Show member pathways
11.69 MYC IL7
3 11.64 MYC BCL6
4 11.32 MYC BCL6
5 11.21 MYC BCL6
6
Show member pathways
10.29 MYC IL7

GO Terms for Lymphoma Aids Related

Biological processes related to Lymphoma Aids Related according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.43 TCL1A MYC IL7
2 positive regulation of B cell proliferation GO:0030890 9.16 IL7 BCL6
3 cytokine-mediated signaling pathway GO:0019221 9.13 MYC IL7 BCL6
4 negative regulation of apoptotic process GO:0043066 8.92 TCL1A MYC IL7 BCL6

Sources for Lymphoma Aids Related

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....